Clinical trials: Insulin
Diabetes Mellitus
A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin.
- Trial name
- NCT01374178
- Testing
- LY2963016, Lantus
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes.
- Trial name
- SWITCH PRO (NCT03687827)
- Testing
- Insulin degludec, Insulin glargine
- Where
- 67 sites in United States, Canada and 4 more
- Volunteers
- 498 people
- Sponsor
- Novo Nordisk A/S
Metabolic Syndrome
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes.
- Trial name
- ATOMICS (NCT00794963)
- Testing
- Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Type 2 Diabetes Mellitus
The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes
The main goals of the study are to evaluate the effect of Exenatide on endothelial-dependent vasodilation, as measured by flow mediated dilation (FMD), to evaluate the effect on endothelial-independent vasodilation, as measured…
- Trial name
- NCT00353834
- Testing
- Exenatide, Glargine Insulin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Joslin Diabetes Center
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Insulin-Dependent
Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
Within 4 weeks after diagnosis of type 1 diabetes, 10 subjects (pubertal males, 12-17 years old) will be randomized to either receive multiple daily injection (MDI) using Lantus insulin, or continuous subcutaneous insulin…
- Trial name
- NCT00357890
- Testing
- Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nemours Children's Clinic
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Primary Objective: To compare lixisenatide versus insulin glulisine in terms of glycosylated hemoglobin (HbA1c) reduction and body weight change at Week 26 in type 2 diabetic participants not adequately controlled on insulin…
- Trial name
- GetGoal-Duo-2 (NCT01768559)
- Testing
- Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID
- Where
- 199 sites in United States, Canada and 16 more
- Volunteers
- 894 people
- Sponsor
- Sanofi
Sarcopenia, Aging
Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults
The loss of muscle mass and strength due to aging leads to serious health problems for older adults. Muscle health can be improved by exercise training, but some people improve their strength substantially, whereas others improve…
- Conditions
- Sarcopenia, Aging, Immune Function
- Trial name
- TDAP2 (NCT02261961)
- Testing
- TDAP, Acute Resistance Exercise, Resistance Exercise Training
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Type 1 Diabetes Mellitus
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
Primary Objective: -To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT02527265
- Testing
- Afrezza
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Depression
Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight
This study will determine whether the drug metformin improves the effects of traditional antidepressant medications in people who are overweight.
- Trial name
- NCT00834652
- Testing
- Sertraline, Metformin
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Washington University School of Medicine
Type 1 Diabetes, Hypoglycemia
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Objective: to gain experience in children and younger adolescents with in-home use of an algorithm that will dose insulin to minimize projected hyperglycemia overnight in addition to suspending the pump if hypoglycemia is…
- Conditions
- Type 1 Diabetes, Hypoglycemia, Hyperglycemia, Artificial Pancreas
- Trial name
- PHM3 (NCT02714972)
- Testing
- Hyperglycemia Minimization Algorithm
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Jaeb Center for Health Research
Gestational Diabetes Mellitus
The Effect of Continuous Glucose Monitoring on Glycemic Control in Insulin-requiring Gestational Diabetes Mellitus
The purpose of this study is to determine if professional Continuous glucose monitoring improves glycemic control with less hypoglycaemia in insulin-requiring Gestational Diabetes Mellitus
- Trial name
- NCT02204657
- Testing
- Continuous Glucose Monitoring System
- Where
- Malaysia
- Volunteers
- 50 people
- Sponsor
- University of Malaya
Diabetic Ketoacidosis
Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)
The study is a multicenter, randomized controlled trial to compare the safety and efficacy of insulin analogs and human insulins both during acute intravenous treatment and during the transition to subcutaneous insulin in…
- Trial name
- NCT00590044
- Testing
- insulin glargine+ glulisine, NPH + Regular insulin
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- Emory University
Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
Glucocorticoids are known to cause an increase in insulin resistance, leading to hyperglycemia, in both diabetic and non-diabetic patients.
- Trial name
- NCT03511521
- Testing
- NPH Insulin, glargine, Insulin Aspart
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood glucose (blood sugar) control on LY2605541 with insulin glargine after 26 weeks of treatment.
- Trial name
- IMAGINE 4 (NCT01468987)
- Testing
- LY2605541, Insulin Glargine, Insulin Lispro
- Where
- 156 sites in United States, Australia and 23 more
- Volunteers
- 1,369 people
- Sponsor
- Eli Lilly and Company
Diabetes, Hypertension
Renal and Hormonal Effects of Pioglitazone
This study examines the effects of pioglitazone on renal sodium handling in subjects prone to insulin resistance, i.e. diabetic and/or hypertensive subjects.
- Trial name
- NCT01090752
- Testing
- Pioglitazone, Metformin
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- University Hospital, Geneva
Type 2 Diabetes Mellitus
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
The purpose of the study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to insulin glargine and metformin with or without thiazolidinediones (TZDs), over a period…
- Trial name
- GetGoal-Duo1 (NCT00975286)
- Testing
- Lixisenatide (AVE0010), Insulin glargine, Pen auto-injector
- Where
- 140 sites in United States, Argentina and 24 more
- Volunteers
- 446 people
- Sponsor
- Sanofi
Type 2 Diabetes
Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes
People who are overweight or who have type 2 diabetes mellitus (T2DM) have higher levels of certain fats in their blood. The blood vessels and heart of most of these individuals do not work normally and people with T2DM also have…
- Trial name
- AcT2 (NCT01580813)
- Testing
- Acipimox
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Background: Pioglitazone has been shown to have potent anti-inflammatory as well anti-atherosclerotic effects. However, the mechanisms by which pioglitazone exerts these effects are not clear.
- Trial name
- PIO-TACE (NCT01223196)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Ovarian Neoplasms
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV…
- Trial name
- NCT00718523
- Testing
- AMG 479
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 170 people
- Sponsor
- Translational Research in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.